Literature DB >> 15812394

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.

Jason W Chien1, Michael B Maris, Brenda M Sandmaier, David G Maloney, Rainer F Storb, Joan G Clark.   

Abstract

Lung function decline is a well-recognized occurrence after myeloablative hematopoietic stem cell transplantation (HCT) that has not been studied after nonmyeloablative conditioning regimens. We examined the lung function of patients before and after 2-Gy total body irradiation-based nonmyeloablative and myeloablative preparative regimens. Before HCT, at day 100, and 1 year after HCT, nonmyeloablative patients had lower 1-second forced expiratory volume (FEV1), forced vital capacity, total lung capacity, residual volume, and carbon monoxide diffusion capacity. However, after transplantation, the risk for experiencing a >20% per year decrease of FEV 1 was significantly lower for nonmyeloablative than myeloablative patients >50 years of age (odds ratio, 0.3; 95% confidence interval, 0.1-0.8; P = .01). Lower pretransplantation FEV 1 was associated with a higher mortality rate for both groups, with the highest mortality risk among patients with a pretransplantation FEV 1 <60% (nonmyeloablative: hazard ratio, 3.9; 95% confidence interval, 1.9-8.0; myeloablative: hazard ratio, 7.2; 95% confidence interval, 2.5-21.2). These results suggest that despite having worse lung function, patients who receive the 2-Gy total body irradiation-based nonmyeloablative regimen will likely experience less pulmonary toxicity than patients who receive a myeloablative regimen, and this may have important clinical implications when deciding on a conditioning regimen for patients >50 years of age with compromised pretransplantation lung function.

Entities:  

Mesh:

Year:  2005        PMID: 15812394     DOI: 10.1016/j.bbmt.2005.01.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

1.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

2.  Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation.

Authors:  Tanyalak Parimon; David K Madtes; David H Au; Joan G Clark; Jason W Chien
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

3.  Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.

Authors:  Filippo Milano; Margaret A Au; Michael J Boeckh; H Joachim Deeg; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-22       Impact factor: 5.742

4.  Pre-hematopoietic stem cell transplant lung function and pulmonary complications in children.

Authors:  Ashok Srinivasan; Saumini Srinivasan; Sudeep Sunthankar; Anusha Sunkara; Guolian Kang; Dennis C Stokes; Wing Leung
Journal:  Ann Am Thorac Soc       Date:  2014-12

5.  Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.

Authors:  Bipin N Savani; Aldemar Montero; Ramaprasad Srinivasan; Anurag Singh; Aarthi Shenoy; Stephan Mielke; Katayoun Rezvani; Shervin Karimpour; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

Review 6.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

7.  Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.

Authors:  Jarrod T Bruce; Jerry M Tran; Gary Phillips; Pat Elder; John G Mastronarde; Steven M Devine; Craig C Hofmeister; Karen L Wood
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-09-15

8.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.

Authors:  Zejing Wang; Mohamed L Sorror; Wendy Leisenring; Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb
Journal:  Br J Haematol       Date:  2010-01-11       Impact factor: 6.998

9.  Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.

Authors:  J Versluis; M Labopin; D Niederwieser; G Socie; R F Schlenk; N Milpied; A Nagler; D Blaise; V Rocha; J J Cornelissen; M Mohty
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

Review 10.  A Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children.

Authors:  Lama Elbahlawan; Ashok Srinivasan; R Ray Morrison
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-25       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.